Content of review 1, reviewed on November 18, 2019
Here are my comments :
I would like to thank the editor for the opportunity to review this manuscript
.
I have the following manuscript:
Major comments:
-There is discrepancy in the total number of included patients (n=24) and table 2 (where n=22), please carefully review and edit as appropriate.
-This manuscript although has valuable results but it needs careful attention to details as :
Minor comments:
-Please review authors affiliations as I believe that not all authors from Egypt
-Line 32: please mention the previously reported dose range.
-Line 62-64: please remove this full reference and put it in the text.
Line 95: please define what you mean by pharmacokinetics in between 2 brackets.
Line 109: 3+3 schema ; please explain this between 2 brackets.
-Line 115: please specify if HCQ was given in equivalent doses to HQ
-Line 164: please add reference to CTCAE.
- Please try to add figure explaining your trial design and different drug doses.
-Line 178: please enumerate ocular toxicity that might happen from your protocol.
Line 184: please explain or delete this sentence “are both censored at 12 months after treatment.
Line 187: No logistic or cox regression was reported, so please this line in statistical analysis section.
Line 187: please add reference to your sentence “No power analysis was needed”
Please delete “)” in line 219
Please exit missing data eg “X” in line 229, range xx to xx in line 207, by… in line 199.
Line 210: adenocarcinoma and sq cell ca of lung origin? Please edit.
Line 257: please add more details.
Paragraph (line 261-268) need to be transferred to the first section in the result and avoid repeated sentences.
Line 286: please add ” ’ ” after patients to be rom patients’ plasma.
-Please spell out abbreviations at their first time eg : ORR, PFS, OS in line 22, ECOG in line 111, G6PD in line 123, AST, ALT, RECIST in lines 125-127, CA in line 245, PBS in line 291
Line: 531: please define “disease control rate “ as a footnote and try to properly fill the table for that with number of patients
Line 543 and 545: please add patients at risk to the Kaplan Meier curves
Source
© 2019 the Reviewer (CC BY 4.0).